Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. The company has developed the world’s most advanced health check for the health industry, providing risk detection for multiple chronic diseases from a single blood sample. Their scalable solution can be applied population-wide at a low cost, replacing many current risk assessments. This allows for effective targeting and tracking of health interventions and better prevention of chronic diseases. Nightingale Health operates globally with a parent company in Finland and subsidiaries in countries including Japan, the United States, Singapore, and the United Kingdom. Their technology is used by leading health initiatives such as the UK Biobank, and is validated by over 600 peer-reviewed publications.

Key milestones include Nasdaq Helsinki listing approval in 2025 with trading commenced on the Main Market, expansion with new laboratories in the UK and US, partnerships with notable organizations like Kaiser Foundation, ZOE, and 23andMe, and the launch of direct-to-consumer services including Livit by Nightingale Health. Founded in 2013 based on scientific innovation, Nightingale Health has grown steadily, expanding into genetics and opening centers of excellence internationally.

Leadership includes CEO and Founder Teemu Suna, CTO and Founder Antti Kangas, and various other executives covering commercial, financial, research, and operational roles. The company also has a distinguished scientific advisory board and a board of directors with industry experts.